NASDAQ · ARCTHealthcarePharmaceuticals

Arcturus Therapeutics Holdings news

$13.69−0.07%

Close Sep 30, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About Arcturus Therapeutics Holdings

mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

GlobeNewswire Inc.Aug 26, 9:46 AM ETNeutral

Listed among leading companies but no specific pipeline achievements, partnerships, or strategic developments are mentioned in the article, limiting sentiment assessment.

Also mentions ARCT

Articles that tag ARCT but are mainly about other companies.

These Are the Only 3 Stocks That Cathie Wood Bought Last Week

The Motley FoolMar 23, 7:07 AM ET▲ Positive

Wood bought on four separate days last week, indicating conviction. Despite declining revenue, the company has positive clinical trial news, strong cash runway until Q2 2028, and promising mRNA technology for rare diseases.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology